ProfileGDS5678 / 1438515_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 59% 59% 58% 60% 60% 60% 58% 58% 56% 58% 55% 58% 59% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5844959
GSM967853U87-EV human glioblastoma xenograft - Control 23.5278759
GSM967854U87-EV human glioblastoma xenograft - Control 33.5317659
GSM967855U87-EV human glioblastoma xenograft - Control 43.4462458
GSM967856U87-EV human glioblastoma xenograft - Control 53.5309660
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.702260
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6576560
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4950858
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4783458
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4093156
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.491158
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3543955
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5207458
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5188759